Everyone. Now, I would like to present to you the result of the first nine months of the fiscal year ending March 31, 2026. In addition to the report on the result of this term, the executive summary of the term, the Americas and the EMEA showed a positive result. China's market environment is still affecting the sales performance. The sales was 98.4%, and operating profit 72.3%, and the quarterly profit was 79% of the same period last year. It is due to the decline of the China's demand for the minimum necessity principle under the government leadership. As a result, on the local currency basis, the China sales was 81% of last year. Operating income was affected by the America's additional tariff, and sales also affected the gross profit. The result of the performance.
Based on that, we will make a downward revision of the forecast to JPY 500,000 for sales and JPY 62 billion for operating profit. That means JPY 10 billion down from the previous forecast for sales and JPY 14 billion down from the previous disclosed forecast. It is due to the decline of the test volume in China and the adjustment of the inventory at the distributors, and also the medical robot business and the delay of the major tender in India. Slide 8, please. The financial highlight. The result of the sales and the operating profits is as just explained, and there was the forex impact. The U.S. dollar is for the Japanese yen appreciation, and euro/yen depreciation, and the Chinese yuan/yen depreciation. That has the impact of JPY 900 million on sales. The forex impact is affecting the operating profit.
For the quarterly profit, the JPY 2 billion for the forex impact, and there's a positive impact of the forex exchange impact. Basically, the quarterly profit is almost on the plan, and we had the Life Science pivot showing the positive impact. Slide 9, sales analysis by business field. In the diagnostic business field, the urinalysis showed a growth, but the hematology, hemostasis, and immunology had a decline in sales. As I mentioned, this is due to the Chinese government policy to control the medical expenditure, and there was the temporary factor in Japan. The medical robot business, it is affected by the Japanese hospitals' severe situation financially. As a result, it's 70.3% of last year. This is the breakdown of net sales by destination and the product type. The specific details of each region will be presented later.
Americas and the EMEA showed a steady growth. On the third quarter, single period basis, both two regions achieved a positive growth from the last year. China is 80% of last year, and Japan was 85.8% of last year. AP region, Asia Pacific region, achieved 4.1% increase, but it was still behind the expectation due to the delay of the major tender deal in India. The third quarter. It's increased by 3.8%, except for China. It's a steady progress. Now slide 11, please. This is for Americas details. North America and Latin America showed a steady growth, and the 9.4%, almost a double- digit growth. It's 5.8% for North America and Latin America, a positive 5.3% increase. Latin America, in total, progressed by 18.9% increase.
The progress of installation of instrument made steady progress, both in hematology and urinalysis field. Amyloid beta reagent also showed a steady growth. In the hematology and hemostasis business, we launched the new model, and the instrument sales started showing progress. To follow the instrument increase in hemostasis, we are also expecting the increase in the reagent sales. The next slide 12, is the EMEA region's detail. This region showed a steady growth in Saudi Arabia, Turkey, and the Middle East are partly affected. It shows a double-digit growth of 12%, and Italy shows 12.7%, and Germany, where our HQ is located, the increase is by 19%. The hemostasis showed a steady progress. There was the major deal in Germany with 40 units of instrument sales, and in East Europe, in Hungary and Czech.
The instrumental sales also drove the performance, and we are expecting the increase of the recurring reagent sales. Some country was behind our expectation. We sell and install instrument, but Siemens Healthineers AG is selling the reagent at a cheaper price than it should be, so we will take some actions against their move. Slide 13, China's detail. As you all know, the government of China is reading the policy to control the medical expenditure. We are taking actions against that. The distributor is adjusting their inventory level, and as a result, the sales was affected. In the hemostasis business, the local knockdown production is showing a steady growth, but in total, the distributor's inventory adjustment is affecting the sales. For the reagent sales in the hemostasis field, the D-dimer and the other parameters are affected by the minimum necessity principle by the government.
As shown at the right bottom, the number of hematology testing itself is remain stable. There is no major change in the trend. Slide 14 has the details of China and its outlook for China. Compared to the last year same period, the fourth quarter's shortfall will be the largest, and it's the impact of the government principle of minimum necessity that will have the nationwide impact. Also, we cannot expect the inventories distributors major deal. These factors will remain in the first half of the next fiscal year, but it will be back on the flat basis in the second half of the next year. As shown at the right bottom, the number of patients are increasing in China because of the aging of the society. The number of hospitals and the beds are increasing, and outpatient are also increasing.
The demand for the healthcare in China itself will show the steady growth. The government started the healthcare spending control several years ago, and this is the necessary step to change the business practices in China. Right now and the immediate future, the situation will be severe for China. After the next fiscal year and on, we will see the new opportunity, and we will present the strategy in our next mid-term plan. Slide 15 is the Asia Pacific details. The major tender deal in India was derailed, but other regions showed a steady progress, and it achieved the increase in sales. There are several major deals in India. The several hundreds of instrument in one deal, or in some cases, the thousands of instrument are expected to be included in the tender. In hemostasis in Malaysia, there was a steady growth.
Other field also showed a steady growth in the reagent sales. The medical robots, four units were installed so far, and it will lead to the increase of the consumables. Slide 16, there was the hematology instrument renewal campaign last year, the backlash. CN-700 and HISCL series changed, and also procalcitonin, the parameter for the sepsis, are showing the steady growth. The medical robotic business is affected by the severe hospital financial situation in Japan, but we are expecting the uplift due to the government subsidy. Now, 96 units are increased, and globally, we have installed 100 units of hinotori system. Slide 17, the breakdown of operating profit. The gross profit changed due to the decline of sales and also the cost ratio increased.
were a major factor, and the R&D expenses and other expenses are controlled. The forex impact was JPY 2.068 billion. Starting with the hemostasis field regarding three growth strategies. We will fully utilize the branding and to allow us to obtain a major tender project. The touch-free concept introduced in XR-Series is also realized in hemostasis area on CN-9000 where we expect to see further expansion. Also the performance of our high-end products are introduced into the compact version like you see on the right-hand side of the picture. We started to launch this product in Japan, and the CN-700 is going to be also expanded into the global market. Also along with the expansion of the installation, we can also see further expansion of reagent business to see improvement in our profitability. Please turn to page 20.
This is about the immunochemistry field. As you can see on the left, last year from December 1st through the 4th in San Diego in the U.S., there was the international conference held about the Alzheimer's disease where we made a presentation. Immunoassay using blood samples regarding MTBR-tau243 was first presented for the first time in the world, and we have gained a lot of expectation from our drug discovery partners as well. Amyloid beta, p-tau217 in addition to them. Now, p-tau205 or tau243 are being developed right now, which is considered to contribute to anti-tau drugs. As you can see on the right-hand side, we have also announced the alliance of the sales with Fujirebio Holdings. Fujirebio, who has abundant product lineup, and Sysmex, we also offer the global sales network.
First we want to expand the business into Brazil and Central and South America and the Middle East. We will also collaborate, reinforce with them and also setting up the guidelines and using HISCL series to be further expanded into the advanced countries. We want to further promote the business in global markets. Next slide. This is the progress in emerging markets. India was already mentioned. As of Q3, we're making the progress so far. From this fiscal year, we started at the start of the local production hematology equipment produced over there. Also in line with the local production guideline, accomplishing Class I level, which is 50% or higher localization level. It was also received the IVD CE mark. We can expect further expansion in the government- related procurement.
The large lab center upgrade at Guild, which is considered to be the top- five player in Brazil market. We were able to be successful in getting this business despite the strong competitor. I guess this is demonstrating our strong branding in the high-end market. In Malaysia, the reference level, which is positioned as in a priority customer by other player, they decided to adopt our product. Their sales revenue is going to be around a little over JPY 100 million per year. It is not just the equipment renewal. We can also address their challenges to improve the productivity and reduce the number of total inspections. Next slide, please, on page 22. Medical robotics business. In Japan, like I said, we are exposed to quite difficult situation so far. We are continuously seeing the weaker appetite for investment.
On the actual field or the medical field, there is a solid need for such as surgery robotics. We are trying to implement flexible sales scheme and also trying to utilize the subsidies for reinforcing the university functions. We want to leverage on them so we can further expand the business. In Asia Pacific area, we are seeing increasing number of cases in Asia market, so we are preparing to support the introduction more into those countries. Europe, we are currently applying for the regulatory application, and we are trying to build the most optimal market model for Europe. Please turn to page 24. Full- year forecast numbers. As I mentioned, executive summary for March 26. The sales will be JPY 500 billion. The operating profit was JPY 62 billion, and the net income to JPY 41 billion. That is how it has been revised.
Please turn to page 25. Because of the slowdown due to the minimum necessity principle in China, we also factored in the major impact on the inventory adjustment. We are expecting a big drop of JPY 8.6 billion in China for the sales. In Japan, due to the medical robotics business, we see a negative JPY 3 billion impact. We have factored in the risks at the maximum. Also we have some FX positive impact. In total, we are looking at to reach JPY 500 billion. For operating profit, we saw the drop in the gross profit due to the sales decline in different location, which was JPY 8.5 billion, which is the largest. Also the product mix impact. We are looking at the impact of negative JPY 7.5 billion, the total JPY 62 billion for the OP.
As I mentioned, in China, year-on-year comparison in Q4, we will see the largest drop. That is what is expected, and including inventory adjustment and the impact of such environmental changes will continue to stay through the first half next year, but it is going to stay flat for the second half, and then eventually start recovering. Please turn to page 26. The first nine-month results, and also according to the revision for the full year and looking at the fourth quarter forecast, there is an impact of the cost of sales, which I will explain the next slide, 27. It is a little tricky. It is a bit complicated page. Looking at Q3 alone, the cost ratio is 49.4%. Compared to last year, it is a difference of 3.7 percentage points from second quarter.
It's going to be worsened by 3.1 percentage points due to the forex and product mix change. For this fiscal year, the China impact, U.S. additional tariff impact. Based on them, for the Q4 alone, the cost ratio is going to be 50.8%. Compared to last year, it's up by 2.4 percentage point, and from the Q3, it's going to up by 1.4 percentage point. It seems like the cost ratio is going to go up due to the increase in instrument sales, and also China impact is affecting this recent forecast. Please go to page 28. This is for your reference. These are the sales by different business and field and destination, just for your reference, especially Americas, EMEA, and Asia Pacific are expected to stay strong. Please go to slide 30. Please move on to the next page.
These are the key points in our next mid-term management plan. As you can see, this mid-term management plan is starting next year, and we are currently drafting this plan. Next month in March, we will be able to explain the backbone, the main part of the mid-term plan. Let me just briefly touch on the key points today. The speed of change in the environment has been getting faster, running healthcare business and the geopolitical issues and economic security- related issues, there's been an increase in uncertainties that we see. If we are able to capture such new needs driven by such changes happening in the world, in the market, that should give us much more business opportunities by developing new market.
Data and AI will be utilized as the core for the digital strategy, we can try to solve the social issues which are felt in medical field. We also want to realize growth of the company at the same time. Flagship product, that's new product to be introduced in a timely manner, which are accommodating the market needs, that way we can meet the customer expectations. In the current mid-term period, especially, we were focusing a lot on Life Science business. We will continue this focus in the next mid-term plan, we can reshuffle our business portfolio to accomplish both growth and profitability. For the capital efficiency will be also another theme to be covered. The investment priority to be clarified and to be clear about the use of the excessive capital, including the dividend policy, and such capital strategy.
It should be put together. Share buybacks is also considered in a positive manner as one of the measure to improve the shareholder values. We will also cover that as part of our mid-term plan to be explained next month. That is all from me. Thank you for your attention